Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas
    Journal Article

    Infante, J. R.; Cassier, P. A.; Gerecitano, J. F.; Witteveen, P. O.; Chugh, R.; Ribrag, V.; Chakraborty, A.; Matano, A.; Dobson, J. R.; Crystal, A. S.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • The epichaperome is an integrated chaperome network that facilitates tumour survival
    Journal Article

    Rodina, A.; Wang, T.; Yan, P.; Gomes, E. D.; Dunphy, M. P. S.; Pillarsetty, N.; Koren, J. 3rd; Gerecitano, J. F.; Taldone, T.; Zong, H.; more...
    Nature (2016)

    Fulltext@MSK | Save
  • First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
    Journal Article

    Abdul Razak, A. R.; Mau-Soerensen, M.; Gabrail, N. Y.; Gerecitano, J. F.; Shields, A. F.; Unger, T. J.; Saint-Martin, J. R.; Carlson, R.; Landesman, Y.; McCauley, D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schòˆder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Safety, efficacy and immune effects of venetoclax 400 mg daily in patients (pts) with relapsed chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Anderson, M. A.; Roberts, A. W.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Kipps, T. J.; Pagel, J. M.; Puvvada, S. D.; Wierda, W. G.; Gressick, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save